about
EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinibNovel oncolytic agent GLV-1h68 is effective against malignant pleural mesotheliomaMET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinibCharacterizing the cancer genome in lung adenocarcinoma.Clinical and in vivo evidence that EGFR S768I mutant lung adenocarcinomas are sensitive to erlotinib.The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Proposals for the Revision of the N Descriptors in the Forthcoming 8th Edition of the TNM Classification for Lung CancerCyclin D1 proteolysis: a retinoid chemoprevention signal in normal, immortalized, and transformed human bronchial epithelial cellsInternational association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinomaSecond primary lung cancers: smokers versus nonsmokers after resection of stage I lung adenocarcinomaRandomized trial of mediastinal lymph node sampling versus complete lymphadenectomy during pulmonary resection in the patient with N0 or N1 (less than hilar) non-small cell carcinoma: results of the American College of Surgery Oncology Group Z0030 TOccult metastases in lymph nodes predict survival in resectable non-small-cell lung cancer: report of the ACOSOG Z0040 trial.Clinical impact of immune microenvironment in stage I lung adenocarcinoma: tumor interleukin-12 receptor β2 (IL-12Rβ2), IL-7R, and stromal FoxP3/CD3 ratio are independent predictors of recurrence.Postinduction positron emission tomography assessment of N2 nodes is not associated with ypN2 disease or overall survival in stage IIIA non-small cell lung cancerThe IASLC Lung Cancer Staging Project: Background Data and Proposals for the Application of TNM Staging Rules to Lung Cancer Presenting as Multiple Nodules with Ground Glass or Lepidic Features or a Pneumonic Type of Involvement in the Forthcoming EThe IASLC Lung Cancer Staging Project: Background Data and Proposals for the Classification of Lung Cancer with Separate Tumor Nodules in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer.Worldwide Esophageal Cancer Collaboration: pathologic staging data.Worldwide Esophageal Cancer Collaboration: neoadjuvant pathologic staging data.Worldwide Esophageal Cancer Collaboration: clinical staging data.Induction chemoradiation and surgical resection for non-small cell lung carcinomas of the superior sulcus: Initial results of Southwest Oncology Group Trial 9416 (Intergroup Trial 0160).Acupuncture is a feasible treatment for post-thoracotomy pain: results of a prospective pilot trialMutational analysis of EGFR and related signaling pathway genes in lung adenocarcinomas identifies a novel somatic kinase domain mutation in FGFR4Visceral pleural invasion: pathologic criteria and use of elastic stains: proposal for the 7th edition of the TNM classification for lung cancer.Dataset for Reporting of Malignant Mesothelioma of the Pleura or Peritoneum: Recommendations From the International Collaboration on Cancer Reporting (ICCR).Patterns of local and nodal failure in malignant pleural mesothelioma after extrapleural pneumonectomy and photon-electron radiotherapy.The IASLC Lung Cancer Staging Project: data elements for the prospective project.Attaining Proficiency in Robotic-Assisted Minimally Invasive Esophagectomy While Maximizing Safety During Procedure Development.FDG-PET SUVmax combined with IASLC/ATS/ERS histologic classification improves the prognostic stratification of patients with stage I lung adenocarcinoma.Esophageal cancer recurrence patterns and implications for surveillanceA nuclear grading system is a strong predictor of survival in epitheloid diffuse malignant pleural mesotheliomaImproved Outcomes with Modern Lung-Sparing Trimodality Therapy in Patients with Malignant Pleural Mesothelioma.Genomic and mutational profiling to assess clonal relationships between multiple non-small cell lung cancers.Supplementary prognostic variables for pleural mesothelioma: a report from the IASLC staging committee.A prospective study of tumor suppressor gene methylation as a prognostic biomarker in surgically resected stage I to IIIA non-small-cell lung cancers.An in vivo platform for tumor biomarker assessment.A cancer staging primer: esophagus and esophagogastric junction.Patterns of recurrence and incidence of second primary tumors after lobectomy by means of video-assisted thoracoscopic surgery (VATS) versus thoracotomy for lung cancer.Prognostic significance of adenocarcinoma in situ, minimally invasive adenocarcinoma, and nonmucinous lepidic predominant invasive adenocarcinoma of the lung in patients with stage I diseaseThe nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma.Pleural intensity-modulated radiotherapy for malignant pleural mesotheliomaMinimally invasive localization of oncolytic herpes simplex viral therapy of metastatic pleural cancer.
P50
Q24561953-674138CB-3591-4FC2-B950-2DB443683D84Q24607747-E15325A2-62F2-46C3-9599-F20C524996CDQ24646295-4E070C48-C8FE-4881-9F89-22F4E118AC05Q24649926-DF174FDA-3DCA-4054-B810-69C093CC38D2Q27853109-32408F3C-82DD-4D09-8125-1174F1D93A74Q28073457-277BD3F5-4860-448B-ACAB-45EC4D53F862Q28137940-E9AEF739-9D60-4496-9C17-0C97B247FB51Q28303718-8FA7606A-E408-4A93-80E5-8D62A6D97BDDQ28392594-475D0664-F18D-4B40-B1F9-C9325115F97EQ30355704-152A41D9-7B13-4217-8026-69100758C51FQ30423999-B2EAC342-DD16-445F-B3AC-6C0EAD07E8B4Q30542070-6E4A6DC1-2124-45FC-9624-BF9AA4F6ABB7Q30730531-A6EA83ED-F847-4A05-BBBA-37738D23DA8CQ31052621-DBF03C6A-6FE2-4FBD-84E3-3DEE9C2BA1DDQ31052628-6EFD0A96-ED85-47E3-9E3C-6EB81CEEDD0CQ31136227-AF7C683F-7A3E-43E0-99E4-A60C8C534B97Q31136229-A42073B3-AF4A-40D5-A704-D6FD471B29D1Q31136233-28775F13-B02D-43BD-BD20-875AACDD3C36Q32158089-A7155CD2-2454-44EB-9F93-29C2FCF393C2Q33242108-AA1D5C54-4CD9-446D-886B-FEFCBF7C4D16Q33283995-ED3AA353-33D5-49FB-914B-5DA7832457BBQ33389791-B3A04C28-9ADF-47E2-BBF9-783CF46F6B30Q33390765-36D77521-9FC5-411F-A9E2-0E7B02DEC539Q33436637-3EA874CC-5079-4477-A7A3-1F02774DABDBQ33450260-3EB9C991-BE78-4450-A8D7-143CF5DAC46BQ33668274-DCC43B6A-5D39-44AF-B80D-C85D7B68A4AFQ33724626-56179037-E25E-434D-910C-D042AEF4C4E5Q33791616-A0BE5412-16F4-4389-8C9D-373C41311F71Q33840661-8A441D2B-D425-424B-8E78-16C9D531F780Q33877584-8EA46748-D7D9-433E-8395-5EE951FAD02DQ33941217-D1EE0492-8AD2-4A60-9BC4-525A80D032F6Q34041728-740F3A78-EDD0-478D-8907-5240D7DBFB83Q34048874-A0483AEC-4843-48E9-ADF7-13C7CFDF03F9Q34064633-CAF1E080-A003-4CE6-82E8-6BD3AE9EA97EQ34100088-6F4DDC86-4959-4E91-A14F-F0CE9563C324Q34148445-789F43D6-7802-457C-A6CB-DBC1C233E6FCQ34181641-5D9D6AB0-AE45-4D16-B245-8D5352D56739Q34190027-8D50892E-674D-4396-9182-EB4C26736F61Q34274850-00A78F2B-8780-471A-B00B-FA8D19681BD2Q34313234-70B1EB67-D8DD-4EFD-A521-89446810727D
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
ricercatrice
@it
հետազոտող
@hy
name
Valerie W Rusch
@ast
Valerie W Rusch
@en
Valerie W Rusch
@es
Valerie W Rusch
@nl
Valerie W Rusch
@sl
type
label
Valerie W Rusch
@ast
Valerie W Rusch
@en
Valerie W Rusch
@es
Valerie W Rusch
@nl
Valerie W Rusch
@sl
altLabel
Valerie W Rusch
@en
prefLabel
Valerie W Rusch
@ast
Valerie W Rusch
@en
Valerie W Rusch
@es
Valerie W Rusch
@nl
Valerie W Rusch
@sl
P214
P244
P106
P21
P213
0000 0000 8111 8211
P214
P244
P31
P496
0000-0003-2345-6900
P735
P7859
lccn-n93802254